Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience

BACKGROUND: Recent observations suggest a lack of humoral response after SARS-CoV-2 vaccination in multiple sclerosis (MS) patients treated with fingolimod or ocrelizumab OBJECTIVES: To assess serological response to SARS-CoV-2 vaccination in MS patients receiving these disease-modifying treatments...

Descripción completa

Detalles Bibliográficos
Autores principales: S., Guerrieri, S., Lazzarin, C., Zanetta, A., Nozzolillo, M., Filippi, L., Moiola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241206/
https://www.ncbi.nlm.nih.gov/pubmed/34189719
http://dx.doi.org/10.1007/s00415-021-10663-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241206/
https://www.ncbi.nlm.nih.gov/pubmed/34189719
http://dx.doi.org/10.1007/s00415-021-10663-x

Ejemplares similares